Recent strategies in the development of taxane anticancer drugs

Bibliography

• WANI MC, TAYLOR HL, WALL ME, COGGON P, MCPHAIL AT: Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. (1971) 93:2325–2327.
   Google Scholar
• GUERITTE-VOEGELEIN F, MANGATAL L, GUENARD D et al: Structure of a synthetic taxol precursor: N-tert-butoxycarbony1-10-deacetyl-N-debenzoyltaxol. Acta Clystallogr. (1990) C46:781–784.
   Google Scholar
• SCHIFF PB, FANT J, HORWITZ SB: Promotion of microtu-bule assembly in vitro by taxol. Nature (1979) 277:665–667.
   PubMed Web of Science ®Google Scholar
• HORWITZ SB: Taxol: mechanism of action andresistance. Stony Brook Symposium on Taxol and Taxotare. Brook, NY, USA (1993):Abstracts 23–24.
   Google Scholar
• NOGALES E, WOLF SG, DOWNING KH: Structure of thea8 tubulin dimer by electron crystallography. Nature (1998) 391:199–203.
   PubMed Web of Science ®Google Scholar
• RAO S, HE L, CHAKRAVARTY S et al.: Characterization ofthe taxol binding site on the microtubule. Identifica-tion of Arg282 in p-tubulin as the site of photoincorpo-ration of a 7-benzophenone analogue of taxol. J. Biol. Chem. (1999) 274:37990–37994.
   Google Scholar
• MANTHEY CL, BRANDES ME, PERERA PY, VOGEL SN: increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J. Immunol. (1992) 149:2459–2465.
   PubMed Web of Science ®Google Scholar
• DING AH, PORTEU F, SANCHEZ E, NATHAN CF: Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science (1990) 248:370–372.
   PubMed Web of Science ®Google Scholar
• NAKANO M, TOMINAGA K, SAITO S et al: Lipopolysac-charide- and paclitaxel (taxol)-induced tolerance in murine peritoneal macrophages lipopolysaccharide-and paclitaxel (taxol)-induced tolerance in murine peritoneal macrophages. J. Endotoxin Res. (1999) 5:102–106.
   Google Scholar
• BOLLAG DM, MCQUENEY PA, ZHU J et al.: Epothilones, anew class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. (1995) 55:2325–2333.
   PubMed Web of Science ®Google Scholar
• TER HAAR E, KOWALSKI RJ, HAMEL E et al.: Discoder-molide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry (1996) 35:243–250.
   PubMed Web of Science ®Google Scholar
• KOWALSKI RJ, GIANNAKAKOU P, HAMEL E: Activities ofthe microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel. J. Biol. Chem. (1997) 272:2534–2541.
   PubMed Web of Science ®Google Scholar
• D'AMBROSIO M, GUERRIERO A, PIETRA F: Sarcodictyin Aand sarcodictyin B, novel diterpenoidic alcohols esterified by (0-N(1)-methylurocanic acid. Isolation from the Mediterranean stolonifer Sarcodictyon roseum. Helv. Chim. Acta (1987) 70(8):2019–2027.
   Web of Science ®Google Scholar
• LINDEL T, JENSEN PR, FENICAL W et al: Eleutherobin, anew cytotoxin that mimics paclitaxel (taxol) by stabilizing microtubules. J. Am. Chem. Soc. (1997) 119:8744–8745.
   Web of Science ®Google Scholar
• KOWALSKI RJ, GIANNAKAKOU P, GUNASEKERA SP et al.:The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel and inhibits the growth of paclitaxel-resistant cells. Mol. Pharmacol (1997) 52:613–622.
   PubMed Web of Science ®Google Scholar
• GIANNAKAKOU P, SACKETT DL, KANG YK et al.: Paclitaxel-resistant human ovarian cancer cells have mutant 8-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. (1997) 272:17118–17125.
   PubMed Web of Science ®Google Scholar
• KOWALSKI RJ, TER HAAR E, LONGLEY RE et al.:Comparison of novel microtubule polymerizing agents, discodermolide and epothilone A/B with taxol. Mol. Biol. Cell (1995) 6:368a.
   Web of Science ®Google Scholar
• HUNG DT, CHEN J, SCHREIBER SL: (-0-Discodermolidebinds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem. Biol. (1996) 3:287–293.
   PubMedGoogle Scholar
• GIANNAKAKOU P, GUSSIO R, NOGALES E et al.: Acommon pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA (2000) 97:2904–2909.
   PubMed Web of Science ®Google Scholar
• OJIMA I, CHAKRAVARTY S, INOUE T et al.: A commonpharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Natl. Acad. ScL USA (1999) 96:4256–4261.
   PubMed Web of Science ®Google Scholar
• WANG M, XIAO X, KIM Y et al.: A unified and quantita-tive receptor model for the microtubule binding of paclitaxel and epothilone. Org. Lett. (1999) 1:43–46.
   PubMed Web of Science ®Google Scholar
• VICTORY SF, GRUNEWALD GL, GEORG GI: Developmentof an epothilone pharmacophore, 215th ACS Meeting., USA (1998):MEDI187.
   Google Scholar
• WINKLER JD, AXELSEN PH: A model for the taxol (paclitaxeD/epothilone pharmacophore. Bioorg. Med. Chem. Lett. (1996) 6:2963–2966.
   Web of Science ®Google Scholar
• HOLTON RA, KIM HB, SOMOZA C et al: First total synthesis of taxol. 2. Completion of the C and D rings. J. Am. Chem. Soc. (1994) 116:1599–1600.
   Web of Science ®Google Scholar
• NICOLAOU KC, YANG Z, LIU JJ et al.: Total synthesis of taxol. Nature (1994) 367:630–634.
   PubMed Web of Science ®Google Scholar
• DANISHEFSKY S, MASTERS J, YOUNG W et al.: Total synthesis of baccatin III and taxol. J. Am. Chem. Soc. (1996) 118:2843–2859.
   Web of Science ®Google Scholar
• WENDER PA, BADHAM NF, CONWAY SP et al.: The Pinene path to taxanes. 6. A concise stereocontrolled synthesis of taxol. J. Am. Chem. Soc. (1997) 119:2757–2758.
   Google Scholar
• MORIHIRA K, HARA R, KAWAHARA S eta].: Enantioselec-tive total synthesis of taxol. J. Am. Chem. Soc. (1998) 120:12980–12981.
   Google Scholar
• MUKAIYAMA T, SHIINA I, IWADARE H et al.: Asymmetric total synthesis of Taxol. Chem-Eur. J. (1999) 5:121–161.
   Web of Science ®Google Scholar
• GUERITTE-VOEGELEIN F, SENILH V, DAVID B, GUENARD, POTIER P: Chemical studies of 10-deacetyl baccatin III. Hemisynthesis of taxol derivatives. Tetrahedron (1986) 42:4451–4460.
   Web of Science ®Google Scholar
• GEORG GI, CHEN TT, OJIMA I, VYAS DM: Taxane anticancer agents: Basic science and current status. ACS Symp. Series 583. American Chemical Society, Washington DC USA (1995).
   Google Scholar
• ARBUCK SG, BLAYLOCK BA: Taxol®: Clinical results and current issues in development. In: Taxof : Science and Applications. Suffness M (Ed.), CRC Press, Boca Raton, USA (1995):379–415.
   Google Scholar
• SEIDMAN AD: Clinical results of taxol in the treatmentof advanced breast cancer: Single agent trials. Stony Brook Symposium on Taxol and Taxotare. Stony Brook, NY, USA (1993):Abstracts 14–16.
   Google Scholar
• TER HAAR E: Taxanes and other microtubule stabilizing agents. Exp. Opin. Ther. Patents (1998) 8:571–586.
   Web of Science ®Google Scholar
• ••A review of patent literature on taxane anticancer agents forthe period of 1995–1997. Initial patents on newly discovered (at that time) microtubule-stabilising agents (epothilones, discodermolide and eleutherobin) were also discussed.
   Google Scholar
• GUENARD D, GUERITTE-VOGELEIN F, POTIER P: Taxol and taxotere: discovery, chemistry and structure-activity relationships. A cc. Chem. Res. (1993) 26:160–167.
   Web of Science ®Google Scholar
• KINGSTON DGI: Recent advances in the chemistry and structure-activity relationships of paclitaxel. In: Taxane AntiCancer Agents: Basic Science and Current Status; ACS Symp. Ser. 583. Georg GI, Chen TT, Ojima I, Vyas DM (Eds.), American Chemical Society, Washington, DC (1995):203–216.
   Google Scholar
• HOLTON RA, BIEDIGER RJ, BOATMAN PD: Semisyn-thesis of taxol and taxotere. In: Taxol° : Science and Applications Suffness M (Ed.), CRC Press, New York, USA (1995):97–121.
   Google Scholar
• BOGE TC, GEORG GI: The medicinal chemistry of 6-amino acids: paclitaxel as an illustrative example. In: Enantioselective Synthesis of-Amino Acids. Juaristi E (Ed.), Wiley-VCH, New York, USA (1997):1–43.
   Google Scholar
• OJIMA I, LIN S, WANG T: The recent advances in the medicinal chemistry of taxoids with novel 6-amino acid side chains. Curr. Med. Chem. (1999) 6:927–954.
   PubMed Web of Science ®Google Scholar
• ••A recent review on the synthesis and biology of taxoids withnovel C-13 I3-amino acid side chains developed in 1996-1999.
   Google Scholar
• SHELANSKI ML, GASKIN F, CANTOR CR: Microtubule assembly in absence of added nuleotides. Proc. Natl. Acad. Sci. USA (1973) 70:765–768.
   PubMed Web of Science ®Google Scholar
• OJIMA I, LIN S: Efficient asymmetric syntheses of p-lactams bearing a cyclopropane or an epoxide moiety and their application to the syntheses of novel isoserines and taxoids. J. Org. Chem. (1998) 63:224–225.
   Web of Science ®Google Scholar
• OJIMA I, LIN S, SLATER JC et al.: Syntheses and biological activity of C3'-difluoromethyl taxoids. Bioorg. Med. Chem. (2000) 8:1576–1585.
   Web of Science ®Google Scholar
• OJIMA I, WANG T, MILLER ML et al.: Syntheses and structure-activity relationships of new second-generation taxoids. Bioorg. Med. Chem. Lett. (1999) 9:3423–3428.
   PubMed Web of Science ®Google Scholar
• •Advanced second-generation taxoids with exceptional activity against drug-resistant breast cancer cell lines were discussed.
   Google Scholar
• APPENDINO G, GARIBOLDI P, GABETTA B et al.: 14-p-Hydroxy-10-deacetylbaccatin-III, a new taxane from Himalayan yew (Taxus-wallichiana Zucc). J. Chem. Soc., Perkins Trans 1(1992) 21:2925–2929.
   Google Scholar
• OJIMA I, LIN S, CHAKRAVARTY S et al.: Synthesis andstructure-activity relationships of novel nor-seco taxoids. J. Org. Chem. (1998) 63:1637–1645.
   Google Scholar
• TISHER RB, GEARD CR, HALL EJ, SCHIFF PB: Taxolsensitizes human astrocytoma cells to radiation. Cancer Res. (1992) 52:3495–3497.
   PubMed Web of Science ®Google Scholar
• O'DONNELL RT, DENARDO SJ, MIERS LA et al.: Combined modality radioimmunotherapy with taxol and 90Y-LYM-1 for Raji lymphoma xenograft. Cancer Biother. Radiopharm. (1998) 13:351–361.
   Google Scholar
• ALLEY MC, SCUDIERO DA, MONKS A et al.: Feasibility of drug screening with panels of human-tumor cell -lines using a microculture tetrazolium assay. Cancer Res. (1988) 48:589–601.
   PubMed Web of Science ®Google Scholar
• BARTOLI MH, BOITARD M, FESSI H et al.: In vitro and invivo antitumoral activity of free and encapsulated taxol. j Microencapsul. (1990) 7:191–197.
   PubMed Web of Science ®Google Scholar
• SHARMA A, STRAUBINGER RM: Novel taxol formulations-preparation and characterization of taxol-containing liposomes. Pharmaceut. Res. (1994) 11:889–896.
   PubMed Web of Science ®Google Scholar
• CHARI RVJ: Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv. Drug. Deliv. Rew. (1998) 31:89–104.
   PubMed Web of Science ®Google Scholar
• ••A general review for the historic and current targetedtherapy of cancer.
   Google Scholar
• KOHLER GMC: Continuous cultures of fused cells antibody of predefined specificity. Nature (1975) 256:495–497.
   PubMed Web of Science ®Google Scholar
• ARAP W, PASQUALLINI R, RUOSLAHTI E: Cancer treatment by targeted drug delivery to tumor vascula-ture in a mouse model. Science (1998) 279:377–380.
   PubMed Web of Science ®Google Scholar
• SAFAVY A, RAISH KP, KHAZAELI MB, BUCHSBAUM DJ, BONNER JA: Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J. Med. Chem. (1999) 42:4919–4924.
   PubMed Web of Science ®Google Scholar
• •The first successful example of tumour-recognising prodrug conjugate for taxane anticancer agents.
   Google Scholar
• TSURUO T, IIDA H, TSUKAGOSHI S, SAKURAI Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. (1981) 41:1967–1972.
   PubMed Web of Science ®Google Scholar
• OJIMA I, BOUNAUD P-Y, FUMERO ODERDA C: Recent strategies for the treatment of multidrug resistance in cancer cells. Exp. Opin. Ther. Patents (1998) 8:1587–1598.
   Web of Science ®Google Scholar
• •A review focuses on patents published in 1996 and 1997 on MDR modulators and alternative approaches to the treatment of MDR tumours.
   Google Scholar
• KOBAYASHI J, OGIWARA A, HOSOYAMA H et al.: Taxuspines A - C, new taxoids from Japanese yew Taxus Cuspidata inhibiting drug transport activity of P-glycoprotein in multidrug-resistant cells. Tetrahe-dron (1994) 50:7401–7416.
   Web of Science ®Google Scholar
• NAITO M, OHHARA T, YAMAZAKI A, DANKI T, TSURUO T:Reversal of multidrug resistance by an immunosup-pressive agent FK-506. Cancer Chemother. Pharmacol. (1992) 29:195–200.
   PubMed Web of Science ®Google Scholar
• MELTON RG, SHERWOOD RF: Antibody-enzyme conjugates for cancer therapy. J. Natl. Inst. (1996) 88:153–156.
   PubMed Web of Science ®Google Scholar
• •A recent review on ADEPT, an efficient approach to release active drug from prodrug at the specific site of tumour.
   Google Scholar